Ann: Imugene OnCARlytics Patent Allowance in China, page-36

"Exclusively licensed to Imugene, OnCARlytics is a CD19-expressing oncolytic virus that
enters solid tumour cells and forces them to express the CD19 protein on the cell surface,
presenting a target for CD19 targeting therapies.
Imugene's OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites
in the United States, with up to approximately 40 patients proposed to take part in the
trial."

IMO, the future intrinsic share value to Imugene for the above Chinese patent will be realized as the data matures, remember that the OASIS study is a dose escalation trial, and that takes time. Expecting a data update shortly.
Expecting a 2025 update on the mice study combination for onCARlytics and Azer-cel from Uman Fong, which is happening in the background at the City of Hope.

Regards.